 |
 |

Efficacy of Varenicline, an 4 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled TrialCorrection
JAMA. 2006;296:1355.
Additional Study Group Member: In the Original Contribution entitled "Efficacy of Varenicline, an 4 2 Nicotinic Acetylcholine Receptor Partial Agonist, vs Placebo or Sustained-Release Bupropion for Smoking Cessation: A Randomized Controlled Trial" published in the July 5, 2006, issue of JAMA (2006;296:56-63), the following name should appear. On page 63, under the Varenicline Phase 3 Study Group, "Raymond Niaura, PhD, Transdisciplinary Research, Butler Hospital, Providence, RI" should appear at the end of the list.
|